Business Wire

Cymulate Reveals Next-level AI Automation for Threat Exposure Validation

18.2.2025 15:00:00 CET | Business Wire | Press release

Share

The company introduces first-of-a-kind automated remediation to eliminate threat exposure, optimize controls and mitigate validated security gaps

Cymulate, the leader in threat exposure validation, today announced the next evolution of the company’s flagship security validation platform. As a pioneer and market leader for breach and attack simulation (BAS) and automated red teaming, Cymulate continues to innovate with automation and artificial intelligence (AI) to deliver the most advanced and easiest-to-use threat exposure validation on the market. At a time when attackers are deploying more advanced tactics than ever, the Cymulate Exposure Validation Platform leverages the power of AI to give every blue and red teamer the automation and accessibility to validate and remediate threat exposure and optimize security.

Exposure validation helps organizations go further than traditional solutions like BAS and automated penetration testing. By embracing the CTEM strategy, security teams can validate their exposure according to their defined threat scope, prioritize contextually according to their specific security strategy, and mobilize while continuously and automatically remediating gaps.

“Security leaders recognize that they need to rapidly address the most exploitable threats in a continuous fashion. Cymulate is bringing first-to-market innovation and automation in our Exposure Validation Platform so security teams can fix their biggest gaps and improve defensive posture before it’s too late,” said Avihai Ben-Yossef, Co-founder and CTO, Cymulate. “We’ve made technologies like attack simulation and automated red teaming easy to implement with actionable findings. Customers are seeing results that reduce noise, clarify decision making and increase the ROI of cyber defense investments.”

The Cymulate Exposure Validation Platform allows security teams to validate their controls alongside potential threats and response tactics, determining which threats are most risky and generating a remediation strategy that prioritizes those exposures first and automates control optimization. Innovative new features include:

  • An AI-powered agent that guides blue teamers and red teamers to create the most impactful validation for their focus – from best practices to industry-specific threats to detailed attack chains from the latest threat intel
  • Streamlined attack simulations that create easier assessments across the MITRE ATT&CK kill chain for all environments, including the most comprehensive library of cloud and Kubernetes attack scenarios
  • A new attack scenario workbench designed to create comprehensive validation assessments from a library of more than one million attack actions or custom scenarios
  • Modular and dynamic assessments that help test for new threats

A key aspect of the Cymulate Exposure Validation Platform is an elevation in the outcome that allows actionable and vendor-specific remediation. Security teams can use their existing stack to manually add optimization rules. Cymulate then automatically pushes these rules to the security controls and automates the entire remediation process.

“The Cymulate Exposure Validation Platform makes advanced security testing fast and easy. When it comes to building custom attack chains, it’s all right in front of you in one place. You can access the full Cymulate library or build your own attack actions,” said Mike Humbert, Cybersecurity Engineer at Cymulate customer Darling Ingredients Inc. “As you start to click and filter, you have the ability to refine what you’re testing, schedule the assessment and drill down to results.”

To learn more about the Cymulate Exposure Validation Platform, visit www.cymulate.com.

About Cymulate

Cymulate, the leader in security and exposure validation, provides the single source of truth for threat exposure and the actions required to close security gaps before attackers can exploit them. More than 1,000 customers worldwide rely on the Cymulate platform to baseline their security posture and strengthen cyber resilience with continuous discovery, validation, prioritization, and guided remediation of security weaknesses. Cymulate automates advanced offensive security testing to validate controls, threats, and attack paths. As an open platform, Cymulate integrates with existing security and IT infrastructure and drives the workflows of the exposure management process. For more information, visit www.cymulate.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250218739287/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

DCX builds coolant chemistry control into its 8 MW Facility Distribution Unit19.10.2026 14:01:00 CEST | Press release

DCX introduces groundbreaking new safety standard protecting critical AI infrastructure by monitoring and keeping the entire coolant loop Continuous monitoring of eight coolant parameters and automatic dosing keep hall-scale liquid-cooling loops in specification between service visits Today DCX Liquid Cooling Systems announced worldwide’s first CDU system with built-in coolant control and treatment system. DCX integrated this coolant quality feature into it’s Facility Coolant Distribution Units: a family of 5-8 MW capable hyperscale-class coolant Distribution Units. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014488003/en/ DCX announces the world’s first CDU with built-in coolant quality control and treatment - a new safety standard for hall-scale Liquid Cooling in critical AI infrastructure. The FDU monitors the chemistry of its coolant continuously and corrects it automatically with integrated electronic dosing pumps

STARTEEPO Sends Letter to Xerox Board in Advance of Third-Quarter Earnings19.10.2026 14:00:00 CEST | Press release

Company’s Third Largest Shareholder Expects Update on Increased Transparency, Strategic Review of Xerox Financial Services Business Unit, and Continued DeleveragingSTARTEEPO Chairman František Bostl to Address Xerox Investment at Skytop Conference in London STARTEEPO SICAV a.s. (“STARTEEPO”), which beneficially owns 7.34% of Xerox Holdings Corporation (“Xerox” or the “Company”) (NASDAQ: XRX) in stocks and options, today issued the following letter to the Xerox Board of Directors (the “Board”): October 19, 2026 The Board of Directors Xerox Holdings Corp. 401 Merritt 7 Norwalk, CT 06851 Dear Members of the Board: Our open letter to the Board in early September helped spark a lively conversation about the future of this iconic company among investors and throughout the print industry. Despite these efforts, Xerox’s share price still does not reflect the significant value we see in the Company, a gap recently confirmed by Citi’s downgrade of Xerox stock to reflect the challenge of executin

The Data Center Marketplace Is Booming, Inaugural Data Center World Europe Unites Data Center and Energy Decision-Makers and Expertsin Vienna19.10.2026 12:00:00 CEST | Press release

Data Center World Europe 2027 took place October 13-15 at VIECON – Vienna Congress & Convention Center in Austria Last week, Data Center World Europe, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators over three days at VIECON – Vienna Congress & Convention Center in Vienna, Austria. It was co-located with the leading global network infrastructure event Network X, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators. Tara Gibb, Senior Director, Data Center World Europe said, “The conference tackled the industry’s most urgent

BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 202619.10.2026 12:00:00 CEST | Press release

New data from four priority programs, including the GPC3x4-1BB bispecific antibody, CEA targeting ADC, CDK4 inhibitor, and brain-penetrant PRMT5 inhibitor underscore the depth of BeOne’s solid tumor pipelineMultiple TEVIMBRA abstracts reinforce breadth of evidence across lung and gastrointestinal cancers, including data in combination with ZIIHERA in HER2+ gastroesophageal cancer BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from across its rapidly progressing solid tumor portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 on October 23-27 in Madrid. Presentations will highlight an accelerating pipeline of differentiated targeted therapies, alongside a broad body of evidence for TEVIMBRA® (tislelizumab), including a late-breaking rapid oral presentation on TEVIMBRA in combination with ZIIHERA® (zanidatamab) in HER2+ gastroesophageal adenocarcinoma (GEA). Priority pipeline data

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication19.10.2026 11:30:00 CEST | Press release

More than half of ENTYVIO patients who met their assigned treatment target reached disease clearance (composite of corticosteroid-free symptomatic, endoscopic and histologic remission) at Week 16VERDICT is the first trial to provide macroscopic and microscopic evidence of intestinal tissue repair associated with disease clearance in largely bio-naïve patients treated with an advanced therapy​ Takeda (TSE:4502/NYSE:TAK) announced new data from VERDICT (NCT04259138), showing that treating adults with intravenous ENTYVIO® (vedolizumab) to achieve corticosteroid-free (CSF) disease clearance versus CSF symptomatic remission alone, resulted in a significantly longer time to first ulcerative colitis (UC)-related complication (hazard ratio 0.33 [95% confidence interval 0.17-0.67]; P=0.0014), reducing UC complication risk by nearly 70 percent. VERDICT, a Phase 4 ENTYVIO clinical trial, provides the first prospective, randomized evidence that disease clearance is an achievable and clinically rel

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye